Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RSG · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Arm AB | EXPERIMENTAL | A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses. |
| Treatment Arm BA | EXPERIMENTAL | A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses. |
| Name | Type | Description |
|---|---|---|
| RSG XR | DRUG | RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water. |
Inclusion Criteria: * Healthy male or female aged 18-55 years. * BMI between 19 - 30 kg/m2 Exclusion criteria: * Liver function tests above the upper limit * Excessive alcohol consumption history * History of Cigarette smoking * Positive HIV, Hep B or C test * Positive pregnancy test * History of...
Top 20 of 24 competitors
RSG is a small molecule being investigated for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development. The drug is being studied for its potential effects on the condition, though it remains investigational and has not been approved for any use.
RSG is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research on this small molecule for Alzheimer's Disease.
RSG is in Phase 1 clinical development. It is an investigational drug being studied for Alzheimer's Disease. The drug has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and potential efficacy.
RSG has one completed clinical trial registered under the identifier NCT00468897. This Phase 1 study was conducted in Germany and enrolled 50 participants. The trial was a controlled, randomized study that included healthy volunteers, with a minimum age of 18 years.
RSG is a designation for the drug rosiglitazone, which is also known by the code name BRL-049653. The clinical trial for RSG specifically studied rosiglitazone XR (extended release) at an 8 mg dose, manufactured at two different sites.